For both the fourth quarter and full year 2025, the increases in R&D expenses were primarily due to higher clinical trial and manufacturing costs associated with the development of soquelitinib as ...
Black Diamond Group’s modeled fair value has shifted from about CA$19.00 to roughly CA$20.46, while bullish analysts are now clustering their price targets in the C$20 to C$22 range. These higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results